Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers explored whether minoxidil, a common treatment for androgenetic alopecia, may have estrogenic activity and found preliminary evidence suggesting it could act as a partial agonist of Estrogen Receptor α (ERα).

5-ARI therapy may help prevent prostate cancer progression.

This study reported that while no synthesized compounds surpassed finasteride in 5α-reductase inhibitory activity, certain 4-azasteroid-2-oximes exhibited notable inhibition.

This case report describes a 31-year-old woman experiencing alopecia areata as a potential side effect of alemtuzumab treatment for relapsing-remitting MS.

This report describes two cases of monilethrix in Afghan siblings, detailing the hair disorder's clinical presentation and potential influences on hair growth, such as hormonal changes and iron supplementation.

In this study, ritlecitinib, an oral JAK3/TEC inhibitor, was evaluated for safety in patients aged 12 and older with alopecia areata across four clinical trials up to 36 months, showing a safety profile with reported adverse events and lab abnormalities summarized per dosing groups.

In this review, researchers examined the current status and advancements in using long-pulse alexandrite lasers for treating hair removal, vascular lesions, and pigmented lesions, aiming to guide clinical use based on how the laser's 755nm wavelength is absorbed by melanin and hemoglobin.

This study reported that CXCL12 may have a dual role in alopecia areata, where decreased levels could impair angiogenesis and disrupt vascular support to hair follicles, while its overexpression might exacerbate autoimmune attacks on hair follicles, contributing to hair loss.

This study found that 4-MA is a potent inhibitor of testosterone 5α-reductase in human tissues, promising potential for treating androgen-dependent skin conditions like male pattern baldness.

In this study, researchers identified compound 30a as a promising topical androgen receptor antagonist that promoted hair growth in mouse models of androgenetic alopecia without noticeable toxicity, suggesting its potential for treating this hair loss condition.

This case series suggests that EE/CMA 0.03mg/2mg may help manage dermatological disorders related to androgen excess, as evidenced by symptomatic improvements in the four patients treated.

In this study, the alcoholic extract of Eclipta alba demonstrated significant anticancer activity in vitro by inducing apoptosis in breast cancer cell lines and showed strong antioxidant properties.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

Azathioprine may be an effective treatment for severe hair loss.

In this study, the researchers found that the picosecond pulsed alexandrite laser (PSAL) may be as effective and safe as the Q-switched alexandrite laser (QSAL) for treating freckles in Chinese patients.

This study reported that etrasimod did not achieve significant improvements in hair regrowth for moderate to severe alopecia areata at 24 weeks, although it showed a dose-dependent trend and was safe and well-tolerated over 52 weeks.

This case report found that a child with acrodermatitis enteropathica showed significant improvement in symptoms after continuous zinc supplementation and identified two SLC39A4 mutations through genetic sequencing.

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

This study demonstrated that the Alopecia Areata Disease Activity Index (ALADIN), a new biomarker, strongly correlates with treatment response in patients using JAK inhibitors for alopecia areata.

This study evaluates the efficacy and safety of a higher dose (100-mg) of ritlecitinib for treating severe alopecia areata, comparing it to external and synthetic placebo control groups.

This article discusses Fluxactive Complete, a natural supplement for prostate health, and reports no new clinical results.

This study found that oral tofacitinib led to clinically significant improvement in alopecia areata severity scores among pre-adolescents, though results varied and further evaluation in clinical trials is needed.

In this randomized controlled study, the researchers found that an herbal extract combination showed similar efficacy to 3% minoxidil solution in treating androgenetic alopecia over 24 weeks, with no significant safety concerns, suggesting it might be a viable alternative treatment.

This study found that a topical treatment combining arginine and zinc significantly reduced hair loss and increased anagen hair percentage in patients with androgenetic alopecia and telogen effluvium, suggesting it might be a promising alternative to finasteride.

This study identified Azithromycin and Roxithromycin as novel senolytic antibiotics that effectively target and reduce senescent human fibroblast cells.

This study found that intralesional methotrexate and triamcinolone acetonide have similar efficacy for localized alopecia areata in adults, but differ in safety profiles, with methotrexate associated with hyperpigmentation and triamcinolone with atrophy.